2
|
Wan L, Zhang Y, Lai Y, Jiang M, Song Y, Zhou J, Zhang Z, Duan X, Fu Y, Liao L, Wang C. Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. J Clin Oncol 2015; 33:3999-4006. [PMID: 26392095 DOI: 10.1200/jco.2014.60.5121] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE For recipients of allogeneic hematopoietic stem-cell transplantation (alloHSCT), we hypothesized that prophylactic therapy during neutropenia with granulocyte-macrophage colony-stimulating factor (GM-CSF) decreases invasive fungal disease (IFD). PATIENTS AND METHODS We randomly assigned 206 patients undergoing alloHSCT to receive once-daily subcutaneous GM-CSF (5 to 7 μg/kg per day), granulocyte colony-stimulating factor (G-CSF; 5 to 7 μg/kg per day), or a combination of G-CSF and GM-CSF (2 to 3 μg/kg per day each). Treatment was started on day 5 after transplantation and was continued until the absolute neutrophil count was ≥ 1.5 × 10(9)/L for 2 consecutive days. The primary outcomes were 100-day incidence of proven and probable IFD and response rate of antifungal treatment. RESULTS For the intent-to-treat population, there was no significant difference in 100-day incidences of proven and probable IFD among the three groups. The antifungal treatment response was better in the GM-CSF group and G-CSF+GM-CSF group than in G-CSF group from day 22 to day 100 (P = .009). The 100-day cumulative mortality after transplantation was lower in the GM-CSF group than in the G-CSF group (10.3% v 24.6%, respectively; P = .037). The GM-CSF and G-CSF+GM-CSF groups had lower 100-day transplantation-related mortality than the G-CSF group (8.8%, 8.7%, and 21.7%, respectively; P = .034). After a median follow-up of 600 days, IFD-related mortality was lower in the groups that received GM-CSF or G-CSF+GM-CSF compared with G-CSF (1.47%, 1.45%, and 11.59%, respectively; P = .016). There were no significant differences in relapse, graft-versus-host disease, or hemorrhage-related mortality among the three groups of patients. CONCLUSION For recipients of alloHSCT, compared with G-CSF, prophylactic GM-CSF was associated with lower 100-day transplantation-related mortality, lower 100-day cumulative mortality, and lower 600-day IFD-related mortality.
Collapse
Affiliation(s)
- Liping Wan
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Yicheng Zhang
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Yongrong Lai
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Ming Jiang
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Yongping Song
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Jianfeng Zhou
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Zhongming Zhang
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Xianlin Duan
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Yuewen Fu
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Lianming Liao
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Chun Wang
- Liping Wan and Chun Wang, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai; Yicheng Zhang and Jianfeng Zhou, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; Yongrong Lai and Zhongming Zhang, First Affiliated Hospital of Guangxi Medical University, Nanning; Ming Jiang and Xianlin Duan, Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi; Yongping Song and Yuewen Fu, Henan Cancer Hospital, Zhengzhou; and Lianming Liao, Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China.
| |
Collapse
|
3
|
Bojarski EF, Strauss AC, Fagin AP, Plantinga TS, Hoischen A, Veltman J, Allsop SA, Granadillo VJA, William A, Netea MG, Dimitrakoff J. Novel PI3Kγ mutation in a 44-year-old man with chronic infections and chronic pelvic pain. PLoS One 2013; 8:e68118. [PMID: 23861857 PMCID: PMC3704649 DOI: 10.1371/journal.pone.0068118] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Accepted: 05/24/2013] [Indexed: 12/31/2022] Open
Abstract
A 44-year-old man is presented here with 14 years of chronic purulent sinusitis, a chronic fungal rash of the scrotum, and chronic pelvic pain. Treatment with antifungal therapy resulted in symptom improvement, however he was unable to establish an effective long-term treatment regimen, resulting in debilitating symptoms. He had undergone extensive work-up without identifying a clear underlying etiology, although Candida species were cultured from the prostatic fluid. 100 genes involved in the cellular immune response were sequenced and a missense mutation was identified in the Ras-binding domain of PI3Kγ. PI3Kγ is a crucial signaling element in leukotaxis and other leukocyte functions. We hypothesize that his mutation led to his chronic infections and pelvic pain.
Collapse
Affiliation(s)
| | - Adam C. Strauss
- Harvard Medical School, Boston, Massachusetts, United States of America
| | - Adam P. Fagin
- Harvard School of Dental Medicine, Boston, Massachusetts, United States of America
| | - Theo S. Plantinga
- Department of Medicine and Nijmegen Institute for Infection, Inflammation, and Immunity, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Alexander Hoischen
- Department of Genetics, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Joris Veltman
- Department of Genetics, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Stephen A. Allsop
- Harvard Medical School, Boston, Massachusetts, United States of America
| | | | - Arsani William
- Harvard Medical School, Boston, Massachusetts, United States of America
| | - Mihai G. Netea
- Department of Medicine and Nijmegen Institute for Infection, Inflammation, and Immunity, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Jordan Dimitrakoff
- Harvard Medical School, Boston, Massachusetts, United States of America
- Department of Surgery (Urology), Harvard Medical School, Boston, Massachusetts, United States of America
- Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts, United States of America
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| |
Collapse
|